ArticleFrontiers in medicine2025
Analysis and prediction of immune cell infiltration characteristics in COPD: Folium isatidis and its active ingredients are able to combat lung lesions caused by COPD by correcting immune cell infiltration.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: As a respiratory disease, chronic obstructive pulmonary disease (COPD) has become a common fatal disease worldwide. We aimed to screen active traditional Chinese medicines (TCMs) for the treatment of COPD by COPD-related transcriptome gene chip analysis and verify their therapeutic activity for COPD. Methods: We used bioinformatics analysis to predict potential therapeutic TCMs based on the immune cell infiltration characteristics in COPD. Further, BALB/c female mice were divided into different treatment groups to investigate the effect of indirubin (IDR) and FI on COPD. After 12 weeks of intranasal lipopolysaccharide instillation and passive smoking, we started giving drug treatment to mice, including distilled water (control and model groups), dexamethasone, IDR and FI. The lung function, visceral index, degree of lung tissue damage, and immune cell infiltration were assessed. Results: We identified 109 differential genes, 22 immune cells, and 50 TCMs associated with the alleviation of COPD. The Conclusion: IDR and FI can ameliorate disease development in COPD model mice by regulating immune cell infiltration. This offers an experimental groundwork for delving deeper into the mechanisms through which TCMs impact COPD treatment and for identifying possible therapeutic drugs for COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.